Dr. Geoffrey Oxnard vice president, global medical lead for Foundation Medicine's liquid biopsy portfolio, stops by Let's Talk Medtech to discuss the company’s recent FDA approvals. Oxnard also gives some insight into the liquid biopsy space.

Omar Ford

November 15, 2020

1 Min Read
IMG_Nov132020at40948PM.jpg
vectorfusionart-stock.adobe.com

Foundation Medicine has been busy with a number of approvals in recent weeks. The company, which was acquired by Roche in 2018 for $2.4 billion, recently won several approvals to be used as companion diagnostics. 

Dr. Geoffrey Oxnard vice president, global medical lead for  Foundation Medicine's liquid biopsy portfolio, stops by Let's Talk Medtech to discuss the company’s recent FDA approvals. Oxnard also gives some insight into the liquid biopsy space and the importance of tissue biopsies.

 

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like